A comprehensive portal site for Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

Jun Yamadera

Eyes, JAPAN co. ltd.

Jun Yamadera founded Eyes, JAPAN co. ltd. in 1995, the first IT startup from the University of Aizu, Fukushima. In the past 20 years, he has been working on various cutting edge projects such as exporting Fukushima rice via web in 1995, making world’s first virtual pottery system, making CG of historical archives of national treasure of Japanese castles, temples, traditional dances and medical motions using motion capture. He is a pioneer in Augmented Reality wearable technologies, Medical x IT and has been organizing world’s first medical security hackathon since 2012. His team won the the championship in Developers Challenge 2013 Health 2.0 in Silicon Valley. He is the Health 2.0 Fukushima Chapter Leader and a TEDxKobe 2015 Speaker. He started a project called “FUKUSHIMA Wheel” in the aftermath of the terrible disaster caused by the earthquake and nuclear accident in Fukushima, JAPAN in March 11, 2011. More than 24 years experience in Cutting Edge Technologies such as AI, Blockchain and Cyber Security. He is also advisor of Safecast and LivingAnywhere.

Tomohiko Goto

TAIYO Pharma Co.,Ltd CMC Solutions Dept. Manager

Having extensive experience and achievements in formulation development, new drug application processes, investigational drug formulation development, support for overseas clinical trials, plant construction and GMP acquisition through long years at a pharmaceutical company, and more recently, engaging in CMC activities for investigational drug development and clinical trial advancement at a medical bio-venture company within Shonan i-Park(Kanagawa,Japan), I hope to contribute as a part-time CMC supporter for MEDISO. I am passionate about supporting the swift delivery of unmet need pharmaceuticals developed by domestic and international medical pharmaceutical venture companies to patients. Among many support areas, if I can contribute my specialized and niche knowledge in the CMC field (particularly in formulation development) to address challenges in cutting-edge bio-venture research worldwide through the MEDISO project, and support quicker entry into clinical trials, it would be most gratifying.

Hiroyuki Kajiyama

Graduated from Kyoto University Faculty of Pharmaceutical Sciences. Worked at Tanabe Mitsubishi Pharma Corporation in pharmaceutical research and development, primarily handling clinical development tasks. Since 2016, employed at the Pharmaceuticals and Medical Devices Agency (PMDA), Review Management Department, as a Technical Expert in Regulatory Science Strategy Consultation. Engaged primarily in providing consultation services on pharmaceuticals, medical devices, regenerative medicine products, focusing on academia and venture companies.

Kunishige Masui

Managing Partner

Graduated from Kyoto University Faculty of Law, University of Tokyo Law School, and University of California, Irvine LLM. 2014 - 2021 at Nagashima Ohno & Tsunematsu; 2020 - 2021 at Smith, Gambrell & Russell, LLP （US law firm）. Established Masui & Partners in December 2021. Mr. Kunishige Masui assisted numerous startups, from angel rounds to companies nearing IPO, and has also assisted in the launch of many new businesses, including cross-border localization. He is well versed in the legal and financing issues that arise for startups and new business development, and provides support as a mentor for JETRO, Healthcare Innovation Hub, Kawasaki-NEDO Innovation Center （K-NIC）, Venture Café Tokyo, and IDEC. In addition to providing easy-to-understand explanations of foreign legal systems in comparison to those in Japan, he also specializes in removing obstacles to business growth by not only providing answers to "points that clients have actually consulted with" but also by digging into "points that need attention that clients are not yet aware of.”

Satoshi Morimoto

Morimoto Phrma Partrnering, Representative

Representative of Morimoto Pharma Partnering. Master of Science in Applied Biochemistry, Graduate School of Waseda University. I stared my carrier at the former The Green Cross Corporation (now Mitsubishi Tanabe Pharma Corporation), experienced in pharmaceutical R&D, product strategy planning, and business development. During that time, I was dispatched as the liaison to Germany for four years. My last position was Director of Business Development. Then, I joined to CMIC Holdings, where I led the business development of rare disease drugs as Director of Business Development and Head of IPD Company. From 2016, I spent six years at the Mitsubishi Chemical Group's Life Science Institute(LSII) as head of the Regenerative Medicine Division, where I was involved in the early stages of cell product development, initiating clinical trials, and leading the construction and operation of cell processing facilities.　After retiring from LSII in 2021, I started own business as a consultant. I would like to provide practical advice based on my experience in the development and commercialization of rare disease drugs and regenerative medicine products. In addition, I would like to provide practical advice on business development from the perspective of having been introduced to various projects from venture companies over 30 years.